- GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients
- GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients
- GeneDx to Participate in Upcoming Investor Conferences
- GeneDx Reports First Quarter 2024 Financial Results and Business Highlights
- GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
- GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024
- GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics
- GeneDx to Participate in 44th Annual Cowen Health Care Conference
- GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024
- GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 27.83 |
---|---|
High | 29.15 |
Low | 27.40 |
Bid | 27.94 |
Offer | 28.08 |
Previous close | 27.76 |
Average volume | 532.76k |
---|---|
Shares outstanding | 26.15m |
Free float | 17.93m |
P/E (TTM) | -- |
Market cap | 725.95m USD |
EPS (TTM) | -5.25 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 17:06 BST.
More ▼